Filing Flows › Alnylam Pharmaceuticals (ALNY) › Capital expenditures
Alnylam Pharmaceuticals (ALNY) capital expenditures by quarter
Alnylam Pharmaceuticals' capital expenditures were $69.8M in Q3 2026 (third quarter 2026), +200% from Q4 2025. Over the last 4 quarters it ranged from $12.1M (Q3 2025) to $69.8M (Q3 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $69.8M | +200% | +475% |
| Q4 2025 | $23.3M | +92% | — |
| Q3 2025 | $12.1M | -15% | — |
| Q2 2025 | $14.3M | — | — |
Q3 2026 at a glance
Alnylam Pharmaceuticals, Q3 2026: revenue $1.5B (+17% year over year), operating margin 23.7%, net earnings $2.2B, operating cash flow $341M. The chart follows the revenue to costs, profit and cash.
Questions
What is Alnylam Pharmaceuticals' capital expenditures?
Alnylam Pharmaceuticals' capital expenditures were $69.8M in Q3 2026 (third quarter 2026), +200% from Q4 2025.
How has Alnylam Pharmaceuticals' capital expenditures changed?
Over the last 4 quarters it ranged from $12.1M (Q3 2025) to $69.8M (Q3 2026).
Q3 2026 results → · How Alnylam Pharmaceuticals makes money →